Company profile: Alzheon

1.1 - Company Overview

Alzheon

Headquarter: United States

Founded: 20XX🔒

Employees: 100-500🔒

🌐 Website

Company description

Provider of clinical-stage treatments for neurodegenerative disorders, including ALZ-801/valiltramiprosate, an oral treatment in Phase 3 testing for Alzheimer’s disease designed to inhibit amyloid oligomer formation; a discovery platform for small molecule inhibitors of protein misfolding; and an expanded access policy for investigational drugs.

Products and services

ALZ-801/valiltramiprosate: An oral treatment in Phase 3 testing for Alzheimer’s disease that specifically inhibits amyloid oligomer formation
Discovery Platform: Develops small-molecule inhibitor products targeting protein misfolding associated with neurodegenerative diseases through a discovery platform
Expanded Access Policy: Delivers investigational-use access to drugs outside clinical trials for patients with serious or life-threatening conditions via an expanded access policy

Key contacts

🔒

Financial details

🔒

1.2 - Competitors and similar companies to Alzheon

PAQ Therapeutics

HQ: United States Website

Description: Provider of an autophagy-based drug discovery platform using ATTEC autophagosome-tethering compounds to degrade disease-causing proteins, lipids, and other substrates. Collaborates with Insilico Medicine to develop small molecule therapies via AI-driven drug discovery, with initial work in a genetic neurodegenerative disorder and plans to expand to diseases lacking treatment options.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full PAQ Therapeutics company profile →

Embera NeuroTherapeutics

HQ: United States Website

Description: Provider of development-stage pharmaceutical therapies for smoking cessation and other addictions with limited or no approved treatments. Developing EMB-001, a patented combination of metyrapone and oxazepam targeting complementary brain pathways and moderating activity in the stress response system. Completed Phase 1 studies in smokers; Phase 2 ongoing in cocaine use disorder and smoking cessation.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Embera NeuroTherapeutics company profile →

Cervel Neurotech

HQ: United States Website

Description: Provider of medical device solutions for non-invasive deep brain neuro-modulation, pioneering an innovative, proprietary approach based on repetitive transcranial magnetic stimulation (rTMS).

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Cervel Neurotech company profile →

MicroTransponder

HQ: United States Website

Description: Provider of neurostimulation medical devices and therapies to treat neurological diseases, including the Vivistim Paired VNS System for post-stroke arm and hand motor recovery, the Serenity System for tinnitus, and the Model 1001 implantable vagus nerve lead. Offers neurostimulation approaches for PTSD, obsessive disorders, phobias, addiction, and motor function improvement.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full MicroTransponder company profile →

Autobahn Therapeutics

HQ: United States Website

Description: Provider of clinical-stage restorative treatments for neuropsychiatric and neuroimmunologic disorders, including ABX-002 (CNS-directed TRβ agonist for major depressive disorder), ABX-003 (next-generation TRβ-selective thyromimetic in IND-enabling studies), ABX-101 (S1P receptor modulator with neuroinflammatory and neuroprotective benefits), and a brain-targeting chemistry platform for tailored CNS/peripheral drug exposure.

Rationale: This competitor operates in a highly similar market segment with overlapping features.

Company type: Private company
Employees: ●●●●●
Total funding raised: $●●●m
Backers: ●●●●●●●●●●
Acquisitions: ●●

View full Autobahn Therapeutics company profile →

🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒

🔒 View all strategic buyers with complete profiles

Start Free Trial →

2.2 - Strategic buyer groups for Alzheon

🔒

Buyer group 1: ████████ ████████

●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Products: ████████, ████████, ████████, ████████

🔒 View all companies in this group

Request Free Trial Now →

🔒

Buyer group 2: ████████ ████████

●● companies

Key Products: ████████, ████████, ████████, ████████

🔒 View all companies in this group

Request Free Trial Now →

🔒

Buyer group 3: ████████ ████████

●● companies

Key Products: ████████, ████████, ████████, ████████

🔒 View all companies in this group

Request Free Trial Now →

🔓 Unlock all detailed buyer group breakdowns with complete company profiles

Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Alzheon

Buyout Funds
50+ funds

🔒

🔒

🔒

🔒

🔒 🇺🇸 Top US buyout funds investing in Alzheon's sector and industry vertical
View Funds →
🔒 🇪🇺 Top Europe buyout funds in Alzheon's sector and industry vertical
View Funds →

2.2 - Growth funds investing in similar companies to Alzheon

Growth Equity Funds
40+ funds

🔒

🔒

🔒

🔒

🔒 🇺🇸 Top US growth equity funds investing in Alzheon's sector and industry vertical
View Funds →
🔒 🇪🇺 Top Europe growth equity funds investing in Alzheon's sector and industry vertical
View Funds →

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Alzheon

4.2 - Public trading comparable groups for Alzheon

🔒

Comparable group 1: ████████ ████████
●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Metrics: Avg EV/Revenue: ●.●x, Avg Growth: ●●%

Revenue growth

Median

15.7%

2025E

16.0%

2026E

EBITDA margin

Median

28.2%

2025E

28.6%

2026E

Cash EBITDA margin

Median

27.6%

2025E

28.0%

2026E

EV/Revenue

Median

8.4x

2025E

6.8x

2026E

EV/EBITDA

Median

28.9x

2025E

24.4x

2026E

EV/Cash EBITDA

Median

29.0x

2025E

25.5x

2026E

🔒 View all companies in this group
Request Free Trial Now →

🔒

Comparable group 2: ████████ ████████
●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Metrics: Avg EV/Revenue: ●.●x, Avg Growth: ●●%

Revenue growth

Median

15.7%

2025E

16.0%

2026E

EBITDA margin

Median

28.2%

2025E

28.6%

2026E

Cash EBITDA margin

Median

27.6%

2025E

28.0%

2026E

EV/Revenue

Median

8.4x

2025E

6.8x

2026E

EV/EBITDA

Median

28.9x

2025E

24.4x

2026E

EV/Cash EBITDA

Median

29.0x

2025E

25.5x

2026E

🔒 View all companies in this group
Request Free Trial Now →

🔒

Comparable group 3: ████████ ████████
●● companies

Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████

Key Metrics: Avg EV/Revenue: ●.●x, Avg Growth: ●●%

Revenue growth

Median

15.7%

2025E

16.0%

2026E

EBITDA margin

Median

28.2%

2025E

28.6%

2026E

Cash EBITDA margin

Median

27.6%

2025E

28.0%

2026E

EV/Revenue

Median

8.4x

2025E

6.8x

2026E

EV/EBITDA

Median

28.9x

2025E

24.4x

2026E

EV/Cash EBITDA

Median

29.0x

2025E

25.5x

2026E

🔒 View all companies in this group
Request Free Trial Now →

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Alzheon

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA

🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Alzheon

What does Alzheon do?

Alzheon is a provider of clinical-stage treatments for neurodegenerative disorders, including ALZ-801/valiltramiprosate, an oral treatment in Phase 3 testing for Alzheimer’s disease designed to inhibit amyloid oligomer formation; a discovery platform for small molecule inhibitors of protein misfolding; and an expanded access policy for investigational drugs.

Who are Alzheon's competitors?

Alzheon's competitors and similar companies include PAQ Therapeutics, Embera NeuroTherapeutics, Cervel Neurotech, MicroTransponder, and Autobahn Therapeutics.

Where is Alzheon headquartered?

Alzheon is headquartered in United States.

How many employees does Alzheon have?

Alzheon has 1,000 employees 🔒.

When was Alzheon founded?

Alzheon was founded in 2010 🔒.

What sector and industry vertical is Alzheon in?

Alzheon is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Alzheon

Who are the top strategic acquirers in Alzheon's sector and industry

Top strategic M&A buyers and acquirers in Alzheon's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Alzheon?

Top strategic M&A buyers groups and sectors for Alzheon include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Alzheon's sector and industry vertical

Which are the top PE firms investing in Alzheon's sector and industry vertical?

Top PE firms investing in Alzheon's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Alzheon's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Alzheon's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Alzheon's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Alzheon include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Alzheon's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Alzheon?

The key public trading comparables and valuation benchmarks for Alzheon include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Alzheon for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Alzheon with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Alzheon's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Alzheon with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Alzheon's' sector and industry vertical?

Access recent funding rounds and capital raises in Alzheon's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Alzheon

Start Free Trial Book a Demo